Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Argatroban is a selective thrombin inhibitor, and previous study had suggested that
argatroban use post percutaneous coronary intervention could potentially prevent reocclusion.
But there has no study on large sample of argatroban treated restenosis vertebral artery
stenting. This study will test the safety and efficacy of the argatroban on prevent Occlusion
and Restenosis in patients with Extracranial vertebral Artery Stenting.